A*STAR IME, SFC Fluidics team up to develop portable diagnostic tool
Unlike conventional diagnostic tools such as neurological tests and computed tomography (CT) scans, the biosensor device does not require any trained personnel for sample handling. The proposed device is a fully-integrated, automated biosensor device which requires only a drop of blood to detect up to three biomarkers released by the brain after sustaining injury.
The biomarker readings will be displayed on an easy-to-read screen, along with an indicator alerting the responding medic or care giver to the severity of the injury, thus helping them determine the proper course of treatment to prevent injury aggravation.
The biosensor device leverages and integrates IME's silicon-based microfluidic sensor and biosensor technology and bio-electrochemical assay development capability. IME has built up strong capabilities in biomedical microsystems and has established deep collaborations with the clinical community and key industry partners in Singapore to advance silicon-based point-of-care diagnostics devices.
"This collaboration exemplifies the extension of "More-than-Moore" technologies to healthcare.�Building on our core capabilities in silicon-based microfluidics and biosensor technology, we can help our partner create innovative diagnostic tools to improve TBI treatment," says Prof. Dim-Lee Kwong, Executive Director of IME.
"By leveraging on IME's industry standard mass production facilities, we can cut down the product development cycle time. The TBI project is the start of a longer term collaboration that SFC will explore together with IME," SFC Fluidics R&D Vice President Dr. Sai Kumar said.